刺激性肠综合征分类系统的稳定性
Mais Khasawneh1,2, Vivek C Goodoory1,2, Cho Ee Ng3
1Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
Alimentary pharmacology & therapeutics
|December 25, 2025
概括
刺激性肠综合征 (IBS) 的分类稳定性各不相同. 便形式和心理负担分类在12个月内最稳定,但没有一种方法完全捕捉到IBS症状波动.
科学领域:
- 胃肠病学 胃肠病学
- 精神病学是一个精神病学.
- 临床研究 临床研究
背景情况:
- 刺激性肠综合征 (IBS) 是一种普遍存在的功能性胃肠疾病.
- 目前的IBS分类依赖于便形式,但症状模式是动态的.
- 这种波动对基于子类型的有效管理提出了挑战.
研究的目的:
- 评估四种不同易怒肠综合征 (IBS) 分类方法的12个月稳定性.
- 使用便形式,最麻烦的症状和两个潜在类分析 (LCA) 模型来评估稳定性.
- 调查包括胃肠道和心理症状在内的全面LCA,以及基于心理负担的简化LCA.
主要方法:
- 从英国注册处招募符合Rome IV标准的IBS参与者.
- 通过验证的在线问卷,在基线和12个月评估胃肠道和心理症状.
- 使用科恩的卡帕统计学来评估分类稳定性.
主要成果:
- 基于便形式的亚型表现出最高的稳定性 (κ=0.60),其中83%的腹占主导地位的IBS病例保持稳定.
- 基于心理负担的分类也显示了中等稳定性 (κ=0.54).
- 隐性类分析 (LCA) 方法,特别是七集群模型 (κ=0.37),在12个月期间表现出较低的稳定性.
结论:
- 现有的IBS分类系统在12个月内仅表现出适度的稳定性,反映了该疾病固有的变化性.
- 便形状和心理负担似乎是最稳定的分类参数.
- 未来的研究应该专注于集成胃肠道和心理因素的动态模型,以改善IBS管理.
更多相关视频
相关概念视频
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
703
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
703
Irritable Bowel Syndrome I: Introduction
879
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
879
Chronic Bowel Disorders: Introduction
721
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
721
Irritable Bowel Syndrome III: Medical and Nursing Management
608
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
608
Drugs for Treatment of Diarrhea-Predominant IBS
590
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
590
Drugs for Treatment of Constipation-Predominant IBS
664
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
664


